קונבריזה

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

BAZEDOXIFENE AS ACETATE 20 MG

Disponible depuis:

NEOPHARM LTD

Code ATC:

G03XC02

forme pharmaceutique:

COATED TABLETS

Mode d'administration:

PER OS

Fabriqué par:

PFIZER IRELAND PHARMACEUTICALS

Groupe thérapeutique:

BAZEDOXIFENE

indications thérapeutiques:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

Date de l'autorisation:

2013-04-01